乘势而上，再启新程丨华夏源江苏淮安细胞药基地开工奠基，细胞药产业再注新动能！

Core Points - The groundbreaking ceremony for the Huaxia Source (Huaian) Cell Drug R&D and Production Base was held, marking the start of a strategic project with a total investment of 1 billion yuan and covering an area of 32.51 acres [1][10] - The project aims to enhance the biopharmaceutical and health industry in Huaian and the Yangtze River Delta region, contributing significantly to the local economy [3][6] Group 1: Project Overview - The Huaxia Source project will create a comprehensive cell technology park that integrates R&D, production, testing, and storage, with a planned construction area of approximately 35,000 square meters [10] - The facility will include a GMP production workshop for pharmaceutical-grade cells, a health management center, and a tumor organ medical testing laboratory, among other components [10][12] - The project is expected to produce approximately 9.5 million bottles of various cell injection solutions annually, positioning it as one of the leading cell drug production bases in China [12] Group 2: Strategic Importance - The establishment of the Huaxia Source base is part of the company's strategy to build a "national cell highway," facilitating the development of a nationwide network for cell therapy [13] - The project is anticipated to attract high-end talent and partners, fostering an innovative ecosystem that promotes the transformation and industrialization of scientific research results in Huaian [7][12] - The collaboration between local government and Huaxia Source reflects a commitment to enhancing the regional biopharmaceutical industry and supporting the "Healthy China" initiative [12][15] Group 3: Technological and Market Position - Huaxia Source has a strong competitive edge in cell therapy, with 436 national patents and a leading number of clinical approvals for its ELPIS® umbilical cord mesenchymal stem cell injection [7][11] - The company plans to leverage its organoid technology platform to accelerate the commercialization of tumor organ services in Jiangsu province, addressing the significant cancer patient population in the region [11][12] - The project will also focus on providing health management services and collaborating with insurance companies to enhance customer engagement and service quality [11][12]